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A B S T R A C T
Background
Invasive fungal infections, important causes of morbidity andmortality in critically ill patients, may be preventable with the prophylactic
administration of antifungal agents.
Objectives
This study aims to systematically identify and summarize the effects of antifungal prophylaxis in non-neutropenic critically ill adult
patients on all-cause mortality and the incidence of invasive fungal infections.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, Issue 3, 2005), MEDLINE
(1966 to 2 September 2005), and EMBASE (1980 to week 36, 2005). We also handsearched reference lists, abstracts of conference
proceedings and scientific meetings (1998 to 2004), and contacted authors of included studies and pharmaceutical manufacturers.
Selection criteria
We included randomized controlled trials in all languages comparing the prophylactic use of any antifungal agent or regimen with
placebo, no antifungal, or another antifungal agent or regimen in non-neutropenic critically ill adult patients.
Data collection and analysis
Two authors independently applied selection criteria, performed quality assessment, and extracted data using an intention-to-treat
approach. We resolved differences by discussion. We synthesized data using the random effects model and expressed results as relative
risk with 95% confidence intervals.
Main results
We included 12 unique trials (eight comparing fluconazole and four ketoconazole with no antifungal or a nonabsorbable agent)
involving 1606 randomized patients. For both outcomes of total mortality and invasive fungal infections, almost all trials of fluconazole
and ketoconazole separately showed a non-significant risk reduction with prophylaxis. When combined, fluconazole/ketoconazole
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reduced total mortality by about 25% (relative risk 0.76, 95% confidence interval 0.59 to 0.97) and invasive fungal infections by about
50% (relative risk 0.46, 95% confidence interval 0.31 to 0.68). We identified no significant increase in the incidence of infection or
colonization with the azole-resistant fungal pathogens Candida glabrata or C. krusei, although the confidence intervals of the summary
effect measures were wide. Adverse effects were not more common amongst patients receiving prophylaxis. Results across all trials were
homogeneous despite considerable heterogeneity in clinical and methodological characteristics.
Authors’ conclusions
Prophylaxis with fluconazole or ketoconazole in critically ill patients reduces invasive fungal infections by one half and total mortality
by one quarter. Although no significant increase in azole-resistant Candida species associated with prophylaxis was demonstrated, trials
were not powered to exclude such an effect. In patients at increased risk of invasive fungal infections, antifungal prophylaxis with
fluconazole should be considered.
P L A I N L A N G U A G E S U M M A R Y
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Critically ill patients are at risk of invasive fungal infections, such as those affecting the bloodstream and other organs. Once established,
such infections are difficult to treat and result in a high mortality. Results from 12 randomized trials demonstrate that the administration
of antifungal drugs to critically ill patients reduces the incidence of invasive fungal infections by about one half and reduces mortality
by about one quarter. Although no increase in adverse effects or resistance amongst fungi was reported by these studies, such effects
are not excluded. However, concerns that the widespread use of antifungal drugs may promote resistance amongst fungi justify their
selective use in patients at greatest risk of fungal infections.
B A C K G R O U N D
The morbidity and mortality caused by invasive fungal infections
amongst hospitalized patients has increased over recent decades
(Beck-Sague 1993; Jarvis 1995). Immunocompromised patients,
such as those with neutropenia (low white blood cells) and organ
transplant recipients, are at particular risk. However, the incidence
of invasive fungal infections in critically ill intensive care unit
(ICU) and surgical patients is increasingly recognized, amongst
whom up to one half of all cases of invasive candidiasis occur
(Ostrosky 2003). Candida species rank as the fourth commonest
cause of bloodstream infection with a reported incidence of 0.5
to 2% of admissions in unselected ICU patients (Borzotta 1999;
McKinnon 2001; Petri 1997; Pittet 1994; Rangel-Frausto 1999).
Patients in ICUs represent a heterogeneous group amongst whom
certain factors, such as recent abdominal surgery, perforation of
the gastrointestinal tract, dialysis, central venous catheterization,
parenteral nutrition, broad-spectrum antibiotic therapy, and colo-
nization with Candida species, are associated with increased risk of
invasive fungal infections (Blumberg 2001; Borzotta 1999; Fridkin
1996; McKinnon 2001;Pittet 1994).
The clinical and economic consequences of invasive fungal infec-
tions in critically ill patients are considerable.Crudemortality rates
of 30 to 40% for candidaemia are commonly reported (Blumberg
2001; Edmond 1999; Fridkin 1996; Petri 1997), but uncertainty
exists regarding the attributable mortality (Blot 2002; Leleu 2002;
Pelz 2000). Candidaemia has been reported to be associated with
prolonged length of ICU stay (Leleu 2002; Pelz 2000) and excess
economic costs as high as US$44,000 per episode (Rentz 1998).
Unfortunately invasive candidiasis is often recognized and treated
late, given the non-specific clinical features and the poor sensitivity
and specificity of currently available diagnostic tests. Recent in-
terest has therefore focused on preventative strategies. Antifungal
prophylaxis, defined as the commencement of antifungal therapy
on the basis of risk factors for infection or colonization with fungi
or both, but without clinical, microbiological, or radiological evi-
dence of a fungal infection, reduces the incidence of invasive fungal
infections in other high-risk patient groups, such as neutropenic
patients (Gøtzsche 2002; Kanda 2000) and solid organ transplant
recipients (Playford 2004). Antifungal prophylaxis, encompass-
ing the terms ’prophylaxis’, ’pre-emptive treatment’, and ’empiric
treatment’, indicates the initiation of antifungal therapy prior to
the definitive diagnosis of a fungal infection. However, the relative
benefits, harms, and cost-effectiveness of antifungal prophylaxis
in non-neutropenic critically ill patients remain undefined. Poten-
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tial ecological effects of widespread antifungal use, including the
selection and spread of resistant fungal strains or species, a well-
recognized phenomenon in bacteria consequent upon antibiotic
use (McGowan 1983), are of particular concern. As a result of this
uncertainty, there is no consensus regarding the use of antifun-
gal prophylaxis in critically ill patients (Calandra 2002; Ostrosky
2003; Rex 2001; Sobel 2001). However, considerable variability
in clinical practice, with respect to the indications for prophylaxis,
the agents used and the duration of prophylaxis, occurs (Gauzit
2003). Given that the overwhelming majority of fungal pathogens
in non-neutropenic critically ill patients involves Candida species,
the azole drugs, fluconazole andketoconazole, have been the agents
in most widespread use for the prophylaxis and treatment of these
infections.
O B J E C T I V E S
The objectives of this review were to determine the benefits and
harms of the prophylactic administration of antifungal agents in
non-neutropenic critically ill patients.
We examined the following primary questions:
1. Is prophylaxis with any antifungal agent(s) associated with
reduced proven invasive fungal infections and total mortality
compared with no prophylaxis?
2. Are some agent(s) alone or in combination more efficacious
than others?
3. For each agent, does the efficacy depend upon dose, route
of administration, and duration of prophylaxis?
4. Do some patient subgroups (e.g. medical versus surgical)
derive greater benefit from antifungal prophylaxis than others?
We examined the following secondary questions:
1. Is antifungal prophylaxis associated with reduced suspected
invasive fungal infections?
2. Is antifungal prophylaxis associated with reduced superficial
fungal infections?
3. Is antifungal prophylaxis associated with reduced fungal
colonization?
4. Is antifungal prophylaxis associated with increased
colonization or infection with azole-resistant fungal strains or
species?
5. Is prophylaxis with antifungal agent(s) associated with
clinically significant toxicity?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomized controlled trials (RCTs) that eval-
uated the effect of any prophylactic antifungal agent (alone or in
combination with other interventions) in non-neutropenic criti-
cally ill patients.
Types of participants
We considered trials involving adult patients (aged 18 years or
over) and paediatric patients (aged less than 18 years), classified as
critically ill (such as those admitted to an ICU or having recently
undergone an abdominal or other major surgical procedure). We
excluded trials involving neutropenic, neonatal or HIV-infected
patients; patients predominantly with malignancies; or solid organ
transplant recipients, as systematic reviews have been or will be
performed for these patient groups (Gøtzsche 2002;Holmes 2003;
McGuire 2004; Playford 2004; Worthington 2004). We included
trials including non-neutropenic critically ill patients along with
other patient groups if the proportion of these is less than 25% or
if data on non-neutropenic patients were separately provided.
Types of interventions
We considered trials if they involved the randomized comparison
of any antifungal regimen with placebo, no antifungal or another
antifungal regimen.
The study groups were required to differ only for the antifungal
regimen under investigation; other cointerventions and aspects of
care, including the routine use of other prophylactic antimicro-
bial agents, were required to be the same to avoid potentially con-
founded comparisons.
Types of outcome measures
Primary outcomes
Primary outcome measures included:
1. Total (all-cause) mortality.
2. Proven invasive fungal infection. The criteria for proven
invasive fungal infection included a clinical illness consistent
with the diagnosis and either histopathological evidence of
invasive fungal infection, or a positive fungal culture from one or
more sterile site specimens (including blood). Funguria (as
indicated by a positive urine fungal culture), in the absence of a
complicated urinary tract infection, and fungal oesophagitis were
classified as superficial fungal infections. Where insufficient
information was available to classify infections, we contacted
study authors for clarification. Otherwise we used the
classification and definitions used in individual studies.
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Secondary outcomes
Secondary outcome measures included:
1. Proven or suspected invasive fungal infection. This
outcome measure incorporated both proven invasive fungal
infection cases (defined above) and suspected invasive fungal
infection cases (defined as the initiation of systemic antifungal
therapy without the fulfillment of the criteria for a proven
invasive fungal infection) in trials that reported both outcomes.
2. Superficial fungal infection. Superficial fungal infections
were defined as superficial cutaneous, oropharyngeal,
oesophageal or uncomplicated urinary tract fungal infections.
3. Fungal colonization. Fungal colonization was defined as a
positive fungal culture from any body site that either developed
(if not present at baseline) or persisted (if present at baseline)
during prophylaxis.
4. Proven invasive fungal infection caused by an azole-resistant
Candida species (defined as Candida glabrata, C. krusei, or
another species with documented azole resistance) or a
filamentous fungus (such as Aspergillus species). Note: although
newer azole antifungal agents (such as voriconazole and
posiconazole) have activity against these fungal pathogens, we
will use the term azole-resistant Candida spp. in this review to
denote fluconazole/ketoconazole resistance.
5. Fungal colonization at any body site with azole-resistant
Candida species.
6. Adverse events requiring cessation of study drug(s).
We analysed all outcomemeasures according to intention-to-treat.
The time point of assessment of outcome measures was at the time
of discharge from ICU or at the end of prophylaxis, whichever
was longer.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases:
The Cochrane Central Register of Controlled Trials (CENTRAL)
(Issue 3 2005): the search strategy incorporated MeSH terms for
antifungal agents and for fungal infections.
MEDLINE (OVID: 1966 to 2 September 2005): the search strat-
egy incorporatedMeSH terms and textwords for antifungal agents
and for fungal infections, combinedwith theCochrane highly sen-
sitive search strategy for identifying randomized controlled trials
in MEDLINE (Dickersin 1994).
EMBASE (OVID: 1980 to week 36 2005): the search strategy
incorporated MeSH terms and textwords for antifungal agents
and for fungal infections combined with a highly sensitive search
strategy for identifying randomized controlled trials in EMBASE
(Lefebvre 1996).
We have included the full electronic database search strategies as
presented in Appendix 1.
Searching other resources
We searched the proceedings of major relevant conferences (in-
cluding, but not limited to: Interscience Congress of Antimicro-
bial Agents and Chemotherapy; American Society for Microbiol-
ogy; Infectious Diseases Society of America; European Congress
of Clinical Microbiology and Infectious Diseases; American So-
ciety of Anaesthesiologists; European Society of Intensive Care
Medicine; and Society of Critical Care Medicine).
We searched the reference lists of identified trials and major re-
views.
We contacted researchers active in the field and primary authors of
identified relevant trials for additional published and unpublished
trial data.
We contacted manufacturers of the study drugs for additional
published or unpublished trial data.
We did not apply a language restriction. We accepted letters, ab-
stracts, and unpublished trials to reduce publication bias. If we
suspected duplicate publication, we contacted the study authors
for clarification, and if confirmed, used the publication with the
longest follow-up data for the review.
Data collection and analysis
Four authors undertook the review (EGP, ACW, TCS, JCC).
Selection of studies
One author (EGP) performed the above search strategy to identify
potentially relevant trials. Two authors (EGP and ACW) then in-
dependently performed each subsequent step of the selection and
review process. The titles and abstracts of identified studies were
initially screened for eligibility. Potentially eligible studies were
subjected to full-text review formethodological quality assessment
(see below) and data extraction (see below). The authors were not
blinded to author, source institution, or publication source of tri-
als. Discrepancies were resolved by discussion with two additional
authors (EGP with TCS and JCC).
Data extraction
Two authors independently extracted and collected data on a stan-
dardized paper form. Where important data regarding trial results
were not provided in the primary papers, we contacted the study
authors for clarification. We extracted data, wherever possible for
all randomized patients on an intention-to-treat basis. One author
(EGP) then entered the data into Review Manager (RevMan 4.2)
twice.
Evaluation of study methodological quality
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We evaluated the validity and design characteristics of each study
for major potential sources of bias (random sequence genera-
tion, allocation concealment, blinding, intention-to-treat analysis,
and completeness of follow-up) (Higgins 2005). We assessed each
study quality factor separately.
Random sequence generation:
Adequate: Method used that would generate random sequence
(e.g. random number generator, toss of coin).
Unclear: No information on random sequence generation avail-
able.
Inadequate: Alternate medical record numbers or other nonran-
dom sequence generation.
Allocation concealment:
Adequate: Allocation method described that would not allow in-
vestigator or participant to know or influence intervention group
before eligible participant entered into study (e.g. central alloca-
tion, sealed opaque envelopes).
Unclear: No information on allocation method available.
Inadequate: Allocation method such as alternate medical record
numbers or unsealed envelopes, open allocation sequence, or any
information in the study that indicated that investigators or par-
ticipants could influence intervention group.
Blinding:
We evaluated whether patients, study investigators, outcome as-
sessors, or data analysis personnel were blinded to treatment allo-
cation.
Intention-to-treat (ITT) analysis:
Yes: Specifically reported by authors that ITT analysis was under-
taken and confirmed on study assessment, or not stated but evi-
dent from study assessment that ITT analysis was undertaken.
Unclear: Reported by authors that ITT analysis was undertaken
but unable to be confirmed on study assessment, or not reported
and unable to be confirmed on study assessment.
No: Lack of ITT analysis confirmed on study assessment (patients
who were randomized were not included in the analysis because
they did not receive study intervention, they withdrew from the
study, or were not included because of protocol violation) regard-
less of whether ITT analysis was reported.
Completeness of follow-up:
Percentage of randomized participants with outcome data at de-
fined study endpoint.
Data analysis
We analysed data using relative risks and 95% confidence intervals
(CI). We assessed heterogeneity across trials with a test of homo-
geneity (χ2 on k-1 degrees of freedom), with p < 0.1 considered
significant. We also applied a test of inconsistency (I2 ) measuring
the proportionof total variation in the estimates of treatment effect
due to heterogeneity between trials (Higgins 2003). We pooled
the results from different trials using a random effects model and
compared with a fixed effect model in a sensitivity analysis. We
performed subgroup analyses according to clinical characteristics
(such as definition of invasive fungal infection, proportion of sur-
gical patients, and medical versus surgical patients) and antifun-
gal prophylaxis regimens (different agents, systemic versus non-
absorbable, dose, duration, and route of administration). We per-
formed sensitivity analyses comparing the random effects model
with a fixed effect model. In a further sensitivity analysis, we as-
sessed the effect of study methodological quality.
We assessed for publication bias using a funnel plot (log relative
risk for efficacy versus 1/standard error) (Egger 1997).
We calculated the number needed to treat (NNT) using the pooled
estimate of relative risk and various assumptions of baseline risk,
whereby NNT = 1 [(baseline risk - (baseline risk · RR)]. We cal-
culated the 95% confidence intervals of the NNT as described
(Altman 1998).
R E S U L T S
Description of studies
From the initial search strategy (2228 potential studies), we iden-
tified 33 references as potentially relevant and retrieved these for
further assessment (Additional Figure 1). Of these, 15 references
(publications and abstracts) reporting twelve trials were eligible
for inclusion in this review (see ’Characteristics of included stud-
ies’: Ables 2000; ARDSNetwork 2000; Eggimann 1999; Garbino
2002; He 2003; Jacobs 2003; Parizkova 2000; Pelz 2001; Sandven
2002; Savino 1994; Slotman 1987; Yu 1993). These twelve tri-
als involved 1606 randomized patients (range, 38 to 292 patients
per trial). Although pharmaceutical companies provided some in-
formation, no unique trials were identified. All identified trials
were published in full: 11 in English and one in Czech (Parizkova
2000).
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Figure 1. Search results
Eight trials compared fluconazole with no antifungal (Ables 2000;
Eggimann 1999; Garbino 2002; He 2003; Jacobs 2003; Parizkova
2000; Pelz 2001; Sandven 2002) and four ketoconazole with no
antifungal or a nonabsorbable agent (Savino 1994; Slotman 1987;
ARDS Network 2000; Yu 1993). All trials but two (He 2003;
Sandven 2002) were restricted to ICU patients. Post-surgical pa-
tients comprised more than 75% of trial participants in six trials
(Eggimann 1999; Pelz 2001; Sandven2002; Savino 1994; Slotman
1987; Yu 1993), 50 to 75% in two (Garbino 2002; Jacobs 2003),
30 to 50% in two (Ables 2000; Parizkova 2000), and not stated
in two (ARDS Network 2000; He 2003). No trials directly com-
pared different marketed systemic antifungal agents, although one
trial compared fluconazole and control with “garlicin” (He 2003).
Reporting of outcomes was variable (see Additional Table 1).
Invasive fungal infections were reported in ten trials. Six trials
(Eggimann 1999; Garbino 2002; Jacobs 2003; Parizkova 2000;
Pelz 2001; Slotman 1987) reported criteria that were consistent
with our definition (i.e. restricted to positive culture or histological
findings,or both, from sterile site/deep tissue specimens), whereas
four trials (Ables 2000; He 2003; Sandven 2002; Savino 1994)
included positive cultures from one or more superficial sites as evi-
dence of invasive infection, which we would consider representing
either colonization or superficial infection (Additional Table 1).
Other outcomes were even more variably reported, particularly
with respect to the fungal species causing infection, colonization,
or both.
Ables et al (Ables 2000) included patients at least 14 years of age
admitted to a single ICU either with a diagnosis of trauma (“code
trauma”, “trauma consult” or “trauma alert”) or who had under-
gone intra-abdominal or intrathoracic surgery. Furthermore, pa-
tients were required to have an anticipated length of ICU stay of
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more than 48 hours and at least one “risk factor” manifest within
48 hours of ICU admission (central venous catheter placement,
administration of total parenteral nutrition (TPN), artificial ven-
tilation formore than 24 hours, or treatment with broad-spectrum
antibiotics). Reported baseline characteristics included mean age
(44 years), mean APACHE II score (18), trauma (70%), intra-ab-
dominal or intra-thoracic surgery, or both (30%), and malignancy
(3%). Patients were randomized to receive either fluconazole (800
mg initially followed by 400 mg daily intravenously, orally, or en-
terally) or placebo (given by same route of administration) for the
duration of ICU stay.
The ARDS Network trial (ARDS Network 2000) included pa-
tients aged at least 18 years admitted to 24 ICUs who were ven-
tilated and who developed acute lung injury or ARDS (impaired
oxygenation and bilateral pulmonary infiltrates). Reported base-
line characteristics included mean age (53 years), mean APACHE
III score (81.3), sepsis (31%), and trauma (10%).Patients were
randomized to receive either ketoconazole (400mgdaily enterally)
or placebo for 21 days or until more than 48 hours of unassisted
ventilation was achieved.
Eggimann et al. (Eggimann 1999) included patients at least 16
years of age admitted to two ICUs with recent abdominal surgery
and who had recurrent gastrointestinal perforation or anastomotic
leakages that were either suspected or confirmed by surgery. Re-
ported baseline characteristics included median age (57 to 63
years),medianAPACHE II score (13), gastrointestinalmalignancy
(37%), pancreatitis (10%), antibiotics (100%), and fungal colo-
nization (40%). Patients were randomized to receive either flu-
conazole (400 mg daily intravenously) or placebo until “complete
resolution of the intra-abdominal disease”.
Garbino et al. (Garbino 2002) included patients over 18 years
of age admitted to a single ICU who were mechanically ven-
tilated for at least 48 hours and expected to remain so for an
additional 72 hours. All patients received selective decontami-
nation of the digestive tract with oral polymyxin B, neomycin,
and vancomycin. Reported baseline characteristics included mean
age (54.3 years), mean APACHE II score (19.4), abdominal
surgery (20%), other surgery (40%), malignancy (15%), antibi-
otics (39%), TPN (28%), and fungal colonization (48%). Pa-
tients were randomized to receive fluconazole (100 mg daily in-
travenously) or placebo until withdrawal from mechanical venti-
lation.
He et al. (He 2003) included patients with pancreatitis and at least
one “predisposing factor” for fungal infection (“gerontism”, dia-
betes, “dysfunction of one or more organs”, hyperglycaemia, cen-
tral venous catheter, TPN, urinary catheterization, “operation”,
gastrointestinal fistula, “ICU”, ventilated at least five days, broad-
spectrum antibiotics at least five days, or “super” broad-spectrum
antibiotics at least three days). Reported baseline characteristics in-
cluded mean age (50.2 years) and mean APACHE II score (12.2),
Patients were randomized to receive fluconazole (100 mg daily in-
travenously), “garlicin” (120 mg daily intravenously), or neither.
Treatment was continued “until relief of predisposing factors”.
Jacobs et al. (Jacobs 2003) included patients admitted a single ICU
with a diagnosis of septic shock (according to criteria established
by the American Society of Chest Physicians/Critical Care Soci-
ety Consensus Conference) within 24 hours of onset, from either
intra-abdominal sepsis or nosocomial pneumonia. Reported base-
line characteristics included pneumonia (52%), intraabdominal
sepsis (48%), surgery (65%), mean APACHE II score (18.4), and
fungal colonization (6%). Patients were randomized to receive ei-
ther fluconazole (200 mg daily intravenously) or placebo for the
duration of the septic shock.
Parizkova et al. (Parizkova 2000) included patients aged at least
18 years of age admitted to a single ICU within five days of ad-
mission who had received at least 24 hours of antibiotic therapy
and at least 48 hours of mechanical ventilation. Reported baseline
characteristics included mean age (44.5 years), mean APACHE
II score (23), gastrointestinal surgery (37%), TPN (97%), broad-
spectrum antibiotics (66%), and central venous access (100%).
Patients were randomized to receive either fluconazole (100 mg
daily intravenously) or no fluconazole until ICU discharge.
Pelz et al. (Pelz 2001) included patients admitted to a single ICU
with an expected length of stay of at least 3 days. Reported base-
line characteristics included median age (63 to 66 years), median
APACHE III score (63 to 65), surgery (91%), TPN (9%), antibi-
otics within 48 hours of ICU admission (29%), central venous
access (95%), malignancy (29%), and fungal colonization (79%).
Patients were randomized to receive either fluconazole (800 mg
loading then 400 mg daily enterally) or placebo until ICU dis-
charge.
Sandven et al. (Sandven 2002) included patients from 13 hos-
pitals with intraabdominal perforation or anastomotic leakage.
Reported baseline characteristics included median age (60 to 68
years), surgery (100%), antibiotics for at least three days (14%),
andmalignancy (40%). Patients were randomized to receive either
fluconazole (400 mg intravenously) or placebo as a single dose.
Savino et al. (Savino 1994) included all patients admitted to a
single ICU formore than 48 hours with an expected ICU length of
stay of at least 48 hours. Reported baseline characteristics included
mean age (54 years), mean APACHE II score (11.3), TPN (42%),
surgery (79%), and malignancy (27%). Patients were randomized
to receive ketoconazole (200 mg daily enterally), clotrimazole (10
mg three times daily enterally), nystatin (2million units four times
daily enterally), or no antifungal until ICU discharge.
Slotman and Burchard (Slotman 1987) included patients admit-
ted to a single surgical ICU with at least three of the following:
age greater than 40 years, second- and third-degree burns cov-
ering greater than 30% of body surface area, antibiotics greater
than seven days, three or more antibiotics, severe sepsis unre-
sponsive to antibiotics, diabetes, steroids greater than seven days,
acute renal failure, immunosuppressive therapy or chemotherapy,
advanced malignancy, TPN, multitrauma, serum glucose greater
than 11.1 mmol/L, intra-abdominal abscess, peritonitis, or se-
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vere head injury. Patients with fungal colonization at baseline
were excluded post-randomization. Reported baseline characteris-
tics includedmedian age (59 to 65 years), intra-abdominal surgery
(39%), other surgery (59%), TPN (25%), antibiotics greater than
seven days (26%), malignancy (11%), and corticosteroids (5%).
Patients were randomized to receive either ketoconazole (200 mg
daily enterally) or placebo for 21 days or until ICU discharge.
Yu and Tomasa (Yu 1993) included patients aged at least 16 years
admitted to a single surgical ICU with a diagnosis of sepsis. Re-
ported baseline characteristics included mean age (53.2 years),
mean APACHE II score (13), and mean number of surgical proce-
dures (1.6 per patient). Patients were randomized to receive either
ketoconazole (400 mg daily enterally) or placebo for 21 days or
until ICU discharge.
Risk of bias in included studies
Although imperfect, the overall methodological quality of the in-
cluded trials was high (see ’Characteristics of included studies’).
Random sequence generation
Adequate random sequence generation was specifically reported
in five trials (Ables 2000; ARDS Network 2000; Eggimann 1999;
Pelz 2001; Sandven 2002) and unclear in the other seven.
Allocation concealment
Adequate allocation concealment was specifically reported in seven
trials (ARDS Network 2000; Eggimann 1999; Garbino 2002;
Jacobs 2003; Pelz 2001; Sandven 2002; Savino 1994) and unclear
in the other five.
Blinding
Blinding of study participants and investigators was reported in
nine trials (Ables 2000; ARDS Network 2000; Eggimann 1999;
Garbino 2002; Jacobs 2003; Pelz 2001; Sandven 2002; Slotman
1987; Yu 1993), with three of these also specifically reporting
blinding of outcome assessors (ARDS Network 2000; Eggimann
1999; Pelz 2001).
Intention-to-treat analysis
Intention-to-treat analysis was apparent in seven trials (ARDS
Network 2000;He 2003; Jacobs 2003; Parizkova 2000; Pelz 2001;
Sandven 2002; Yu 1993).
Completeness of follow-up
Post-randomization exclusions were greater than 10% in two trials
(Eggimann 1999; Slotman 1987).
Effects of interventions
Total mortality
(see Analysis 1.1)
Although total mortality rates were very variable in the control
arms of the seven fluconazole trials reporting this outcome (range
0-54%, mean 26%), there was no significant heterogeneity in the
observed effect of fluconazole across these trials (χ2 = 8.73, df =
6, p = 0.19; I2 = 31.3%). One trial (Jacobs 2003) demonstrated
a significant mortality reduction (RR 0.41, 95% CI 0.2 to 0.83)
with fluconazole, with four other trials (Eggimann 1999; Garbino
2002; Pelz 2001; Sandven 2002) showing a small, non-significant
benefit. The summary relative risk favoured fluconazole, but was
not significantly less than 1.0 (RR 0.77, 95% CI 0.56 to 1.07).
Mortality in the control arms of the four ketoconazole trials ranged
from 16-42% (mean 25%), with some heterogeneity evident (χ
2 = 6.28, df = 3, p = 0.1, I2 = 52.3%). The results of three trials
(Savino 1994; Slotman 1987; Yu 1993) favoured ketoconazole,
with the pooled analysis demonstrating a non-significantmortality
reduction (RR 0.68, 95% CI 0.42 to 1.12).
Across all eleven trials, the results were homogeneous (χ2 = 14.81,
df = 10, p = 0.14, I2 = 32.5%), demonstrating a significant reduc-
tion in total mortality by about 25% (RR 0.76, 95% CI 0.59 to
0.97).
Invasive fungal infections
(see Analysis 1.2)
Fluconazole significantly reduced the incidence of proven invasive
fungal infections by about one half (RR 0.47, 95% CI 0.32 to
0.71). One trial (Parizkova 2000) did not report any proven infec-
tions, whereas amongst the other seven fluconazole trials, the inci-
dence ranged from 3% to 41% (mean 15%). Despite differences
in the dose, route of administration, and duration of fluconazole
prophylaxis, there was no significant heterogeneity in the relative
risk reduction across studies (χ2 = 1.12, df = 6, p = 0.98, I2 = 0%).
Amongst the two ketoconazole trials that reported invasive infec-
tions, no significant reduction was demonstrated, although confi-
dence intervals were wide (RR 0.3, 95% CI 0.07 to 1.31).
Across all trials of both fluconazole and ketoconazole, the results
were homogeneous (χ2 = 1.82, df = 8, p = 0.99, I2 = 0%), with a
significant reduction in invasive infections by about one half (RR
0.46, 95% CI 0.31 to 0.68).
Proven or suspected invasive fungal infections
(see Analysis 1.5 and Analysis 1.6)
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Fluconazole prophylaxis did not significantly reduce the incidence
of suspected invasive fungal infections (empiric antifungal use)
amongst the four trials that reported this outcome, although some
heterogeneity was evident (χ2 = 6.72, df = 3, P = 0.08, I2 = 55.4%)
and the confidence intervals were wide (RR 1.14, 95% CI 0.25
to 5.13). The incidence of suspected invasive fungal infections in
the control arms of the fluconazole trials ranged from 1% to 5%
(mean 3%).
The combined incidence of proven and suspected invasive fungal
infections in the control arms of the four fluconazole trials report-
ing this outcome ranged from 14% to 22% (mean 17%). Flucona-
zole prophylaxis was associated with a nonsignificant reduction in
their incidence (RR 0.64, 95% CI 0.4 to 1.02).
Superficial fungal infections
(see Analysis 1.7)
The incidence of superficial fungal infections in the control arm of
the three fluconazole trials that reported this outcome ranged from
3% to 12% (mean, 6%). Fluconazole prophylaxis demonstrated
a non-significant reduction in superficial fungal infections (RR
0.59, 95% CI 0.27 to 1.29), with no significant heterogeneity
demonstrated across these three trials (χ2 = 1.12, df = 2, P = 0.57,
I2 = 0%).
Fungal colonization
(see Analysis 1.8)
Fluconazole prophylaxis reduced the incidence of fungal coloniza-
tion by about one half (RR 0.55, 95% CI 0.42 to 0.74): this effect
was homogenous across the four trials reporting fungal coloniza-
tion (χ2 = 3.61, df = 3, P=0.31, I2 = 16.9%). Ketoconazole also
reduced fungal colonization (RR 0.66, 95%CI 0.47 to 0.94), with
no significant heterogeneity demonstrated across the three trials
(χ2 = 0.83, df = 2, P = 0.66, I2 = 0%). Across the fluconazole and
ketoconazole trials, the effect on fungal colonization was homoge-
nous (χ2 = 4.72, df = 6, P = 0.58, I2 = 0%). Reporting of fungal
colonization did not allow for stratification of colonized patients
into those with or without fungal infection.
Infection and colonization with azole-resistant fungi
(see Analysis 1.3, Analysis 1.4 and Analysis 1.9)
Infections with C. glabrata or C. krusei were documented in four
of the six fluconazole trials that provided data on the species of
invasive fungal pathogens (Ables 2000; Eggimann 1999; Garbino
2002; Pelz 2001). Amongst these four trials, infections with C.
glabrata orC. krusei accounted for 16% of all invasive infections in
the control arms and 21%in the fluconazole arms. The incidence
of proven invasive infections caused by azole-resistant Candida
species was not significantly increased with either fluconazole (RR
0.66, 95%CI 0.22 to 1.96) or ketoconazole prophylaxis (RR 0.34,
95% CI 0.01 to 8.14).
Fungal colonization with C. glabrata or C. krusei occurred in 6%
and 15% in the control and fluconazole arms, respectively. Al-
though no significant effect of fluconazole on colonization with
azole-resistantCandida species was demonstrated, three of the four
fluconazole trials did report greater colonization rates and the con-
fidence intervals around the pooled estimate were very wide (RR
1.74, 0.64 to 4.71).
Adverse events
(see Analysis 1.10)
Adverse events requiring cessation of systemic antifungal prophy-
laxis were very uncommon and did not occur more frequently
than in the control arms.
Subgroup and sensitivity analyses
(see Additional Table 2)
In subgroup analyses, no obvious effect of clinical characteristics
or antifungal prophylaxis regimenwas evident. Sensitivity analyses
similarly did not demonstrate an effect of analysismethod (random
effects or fixed effect models) or study methodological quality.
Publication bias
(see Additional Figure 2 and Additional Figure 3)
Although trial numbers were relatively small, some degree of asym-
metry in the funnel plot of precision by effect size was evident,
with a relative absence of trials reporting a lack of benefit from
antifungal prophylaxis.
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Figure 2. Funnel plot for systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal;
outcome = total mortality
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Figure 3. Funnel plot for systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal
agents; outcome = proven invasive fungal infection
D I S C U S S I O N
This meta-analysis demonstrates that antifungal prophylaxis in
non-neutropenic critically ill patients reduces proven invasive fun-
gal infections by approximately one half and total mortality by
approximately one quarter.
Although none of the individual fluconazole trials demonstrated a
significant reduction in invasive infections, the pooled result was
highly significant. Furthermore, the efficacy of fluconazole was
remarkably consistent across the studies despite considerable dif-
ferences in the dose, duration, route of administration, and other
clinical and methodological aspects. This suggests that the results
are generalizable to a diverse range of clinical situations. Assuming
a baseline incidence of invasive fungal infections amongst unse-
lected critically ill patients of 2% (Rex 2001), 94 patients would
require fluconazole prophylaxis to prevent one infection. This esti-
mate varies according to risk (see Additional Table 3): ranging, for
example, from nine amongst higher risk patients (with an approx-
imate 20% incidence) to 188 amongst lower risk patients (with
an approximate 1% incidence). A similar - albeit non-significant
- effect was observed with ketoconazole on the basis of two trials
reporting this outcome.
Demonstration of a beneficial effect of antifungal prophylaxis on
total mortality is novel and important. The point estimates of
seven of the 11 trials favoured antifungal prophylaxis, whereas two
showed no benefit. Overall there was no significant heterogene-
ity with results across the trials. The pooled analysis for flucona-
zole prophylaxis suggests a 23% mortality benefit, with relatively
wide confidence intervals (from a 7% hazard to a 44% benefit).
However, inclusion of the ketoconazole trials in the pooled anal-
ysis demonstrates a significant result of about the same magni-
tude (24% mortality benefit, 95% CI 3% to 41%). These find-
ings are highly encouraging. Although the confidence intervals are
wide and individually only one trial reported a significant mor-
tality benefit, seven of the other ten trials did demonstrate a non-
significant benefit. However, whether this mortality benefit is me-
diated through preventing invasive fungal infections remains un-
certain. Reported crude mortality rates associated with such in-
fections in critically ill ICU patients which range between 40%
and 60% (Blumberg 2001; Edmond 1999; Fridkin 1996; Petri
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1997) do not account for the confounding effect of severity of
illness. Estimates of the attributable mortality from epidemiolog-
ical studies comparing the mortality of infected with uninfected
patients matched for severity of illness, have yielded conflicting
results. We must note the difficulties of adequately accounting
for the influence of all factors confounding the association be-
tween critical illness, fungal infections, and mortality: two stud-
ies demonstrated no significant attributable mortality (Blot 2002;
Pelz 2000) whereas one demonstrated a 31% attributable mor-
tality (Leleu 2002). Given an uncertain attributable mortality, it
remains possible that merely preventing fungal infections may not
prevent deaths in critically ill patients who are at risk of death
from other underlying conditions. Of note is that antifungal pro-
phylaxis has not been demonstrated to reduce total mortality in
other high-risk patients, such as neutropenic patients (Gøtzsche
2002) or solid organ transplant recipients (Playford 2004). Fun-
gal-related mortality may be reduced with antifungal prophylaxis
amongst neutropenic patients (Kanda 2000); however we deliber-
ately did not assess this outcome in this study, as we considered the
attribution of deaths to fungal infections imprecise and subjective,
and therefore prone to bias. Ketoconazole and fluconazole exert
anti-inflammatory and immunomodulatory effects in addition to
their antifungal activity (Williams 1992; Zervos 1996), and other
mechanismsmay therefore contribute to any mortality benefit. In-
deed such effects provided the rationale for three of the ketocona-
zole and one of the fluconazole trials in patients with acute respi-
ratory distress syndrome or septic shock (ARDS Network 2000;
Jacobs 2003; Slotman 1987; Yu 1993). In summary, this system-
atic review suggests that azole prophylaxis reduces total mortality
in critically ill ICU patients consistently across the available trials
and, when pooled, this mortality benefit is significant. Although
promising and potentially clinically important, the identification
of those patient subsets, amongst the typically heterogeneous ICU
population, that are likely to derive the greatest benefit remains
an important objective. Confirmation of this mortality benefit in
appropriately powered clinical trials amongst such patients is war-
ranted.
The selection of resistant fungal species is a major potential ad-
verse consequence of widespread antifungal use. Certain Candida
species, such as C. glabrata and C. krusei, and most filamentous
fungi, including Aspergillus species, are intrinsically or relatively
fluconazole-resistant. The de novo development of fluconazole-
resistance amongst susceptible species and the emergence of in-
trinsically resistant species have been associated with the use of
antifungal agents, particularly amongst neutropenic or HIV-in-
fected patients (Abi-Said 1997;Gleason 1997; Johnson 1995; Law
1994; Nguyen 1996).Whether such use amongst critically ill ICU
patients has resulted, or will result, in a similar phenomenon re-
mains uncertain. In the fluconazole trials reporting the species
of infecting fungal pathogens, no significant increase in invasive
infections or colonization caused by C. glabrata or C. krusei was
demonstrated, although more patients were colonized with these
species in the fluconazole arms of three of four trials. Thewide con-
fidence intervals around these pooled estimates reflect relatively
small event rates and insufficient sample sizes. Thus, that flucona-
zole prophylaxis may predispose to infection or colonization with
azole-resistant fungal species cannot be excluded from the avail-
able studies and further studies involving the characterisation and
susceptibility testing of fungal isolates, an appropriate timeframe,
and sufficient statistical power are required.
The trials included in this review are insufficiently powered to ex-
clude adverse toxic events. Ketoconazole - and to a lesser extent
fluconazole - have been associated with hepatotoxicity and clini-
cally-important drug interactions. The likelihood and severity of
such events with routine antifungal prophylaxis require careful
consideration.
The major limitation of this systematic review is the relatively
small number of trials and their small sample sizes causing impre-
cision of pooled estimates. We sought to maximize study retrieval
by employing a comprehensive search strategy encompassing the
major computerized databases without language restriction, major
conference proceedings, unpublished studies, and review articles.
We approached major pharmaceutical companies marketing anti-
fungal agents, but identified no additional or unpublished studies.
Despite these efforts, some degree of funnel plot asymmetry was
evident, which suggests the possibility of publication bias.
The methodological quality of studies in this review, as reported,
was generally of high standard. In more than half of the trials,
adequate allocation concealment, an important potential source
of bias if inadequate (Schultz 1995) was reported. As invasive
fungal infections are often diagnosed with some degree of un-
certainty and subjectivity, blinding of outcome assessors with re-
spect to treatment allocation would be an important precaution
to minimize bias. However, this precaution was specifically re-
ported in only three trials. Despite progress toward standardiza-
tion (Ascioglu 2002), a varied, and often conflicting, range of
diagnostic criteria for invasive fungal infections has been pub-
lished (Ascioglu 2001). This problem was evident amongst the
trials reviewed here.We therefore, wherever possible, restricted the
diagnosis to patients with compatible clinical features in whom
fungi were demonstrated in blood or deep tissue specimens by
histopathology, culture, or both. Four trials also included positive
cultures from nonsterile site specimens as evidence of invasive in-
fections making independent classification of infections impossi-
ble. Although in this review, the direction and magnitude of trial
results did not appear to correlate with the presence or absence
of reported study methodological quality parameters, we urge the
incorporation and reporting of methodological quality parame-
ters and the adoption of standardized diagnostic criteria for future
trials.
Despite heterogeneity of the clinical as well as the methodologi-
cal aspects of the trials, the results for the major outcomes were
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remarkably homogeneous. This finding suggests that pooled esti-
mates are both robust and applicable across a wide range of clin-
ical situations encountered with critically ill patients. Although
likely that different antifungal regimens have different efficacies,
the results of this meta-analysis suggest that, overall, they are of
a similar magnitude. Nevertheless, given the lack of head-to-head
comparative trials, inferences regarding the superiority of different
doses, routes of administration, and durations of antifungal pro-
phylaxis are not possible. Fewer data are available for ketocona-
zole, although the results of this review indicate an overall similar
effect to fluconazole. This is an interesting result, given the poor
and erratic bioavailability of the oral formulation. However, firm
conclusions regarding the relative efficacies of fluconazole and ke-
toconazole are restricted by the lack of direct head-to-head com-
parative trials.
Other antifungal agents, such as itraconazole, voriconazole, posi-
conazole, caspofungin, and amphotericin B, possess broader spec-
tra of activity than fluconazole, but have not been assessed in ran-
domized controlled trials of prophylaxis in non-neutropenic criti-
cally ill patients. Given thatCandida species cause the overwhelm-
ing majority of infections in such patients and the demonstrated
efficacy and safety of fluconazole, there may be little rationale for
their use. Such agents may be justified in situations where flu-
conazole-resistant candida infections are prevalent, although their
routine use may simply exert additional selection pressure and an
increase in resistant isolates.
Given its demonstrated efficacy in preventing fungal infections,
should fluconazole prophylaxis be adopted in critically ill patients?
Amongst such patients, the risk of fungal infections varies from
patient to patient and antifungal prophylaxis should therefore be
instituted selectively to patients at increased risk, rather than uni-
versally. Many risk factors for fungal infections have been defined
(Ostrosky 2003; Paphitou 2005) and should be incorporated into
decisions regarding prophylaxis (see Additional Table 3).However,
the accurate identification of patients at increased risk requires the
further refinement and validation of predictive risk assessment al-
gorithms (Ostrosky 2003; Paphitou 2005). Furthermore, the cost-
effectiveness of antifungal prophylaxis strategies has not been de-
fined - awaiting, in part, a clearer understanding of the attributable
clinical and economic consequences of invasive fungal infections
in critically ill patients. Finally, as the selection or generation of
resistance to antifungal agents among fungal pathogens remains a
major potential concern, further study quantifying such potential
ecological effects is required before the widespread adoption of
antifungal prophylaxis can be recommended.
In summary, this systematic review and meta-analysis demon-
strates that antifungal prophylaxis with fluconazole or ketocona-
zole reduces invasive fungal infections and total mortality across
a broad range of clinical settings in non-neutropenic critically ill
patients. Antifungal prophylaxis is thus recommended for criti-
cally ill patients at increased risk of invasive fungal infections. Al-
though no significant difference in the effect of fluconazole and
ketoconazole was demonstrated, fluconazole is preferred given the
greater available evidence-base, its more favourable pharmacoki-
netic properties, its availability in either parenteral or enteral for-
mulation, and its safer toxicity and drug interaction profile.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our results demonstrate that antifungal prophylaxis, particularly
with fluconazole, is effective in preventing invasive fungal infec-
tions and total mortality in non-neutropenic critically ill patients,
although the optimal dose and duration of prophylaxis remain
uncertain. Antifungal prophylaxis with fluconazole should there-
fore be considered for patients at increased risk of invasive fungal
infections.
Implications for research
The prospective identification of patients at increased risk, who
may most benefit from antifungal prophylaxis, from amongst the
general populationof critically ill patients requires further research.
Althoughmany risk factors for fungal infections have beendefined,
these require integration into risk predictive algorithms (Ostrosky
2003; Paphitou 2005). The cost-effectiveness of antifungal pro-
phylaxis strategies also has not been defined - awaiting, in part,
a clearer understanding of the attributable clinical and economic
consequences of invasive fungal infections in critically ill patients.
The selection or generation of resistance to antifungal agents
among fungal pathogens remains a major potential concern and
further study quantifying such potential ecological effects is re-
quired before the widespread adoption of antifungal prophylaxis
can be recommended.
The significant effect of antifungal prophylaxis with fluconazole
and ketoconazole on total mortality demonstrated in this study is
promising and potentially clinically important; this requires con-
firmation in appropriately powered trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ables 2000
Methods Random sequence generation: Yes (block)
Allocation concealment: Unclear
Blinding (subjects/investigators): Yes
Blinding (outcome assessors): Unclear
Intention-to-treat analysis: No
Number excluded /number randomized: 6/125 (5%)
Participants Inclusion: trauma or surgical patients, expected length of stay >48 hours, >1 risk factor (e.g. central venous
line, total parenteral nutrition, mechanical ventilation, antibiotics etc)
Number randomised: 125
Percentage post-surgical: >30%Candida at baseline: 24%
Percentage colonized with Candida at baseline: 24%
Interventions 1. Fluconazole 800 mg/day intravenously (IV) initially then 400 mg/day IV or orally
2. Placebo
Intervention duration: until ICU discharge (maximum 6 weeks)
Outcomes Mortality
Proven IFI
Suspected IFI
Proven IFI with azole-resistant species
Superficial FI
Fungal colonization
Fungal colonization with azole-resistant species
Adverse events
Follow-up duration: until hospital discharge
Notes Country: USA
Setting: single hospital, adult ICU
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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ARDS Network 2000
Methods Random sequence generation: Yes (computer)
Allocation concealment: Yes (central allocation)
Blinding (subjects/investigators): Yes
Blinding (outcome assessors): Yes
Intention-to-treat analysis: Yes
Number excluded /number randomized: 0/234 (0%)
Participants Inclusion: acute lung injury
Number randomized: 234
Percentage post-surgical: not stated
Percentage colonized with Candida at baseline: not stated
Interventions 1. Ketoconazole 400 mg/day orally
2. Placebo
Intervention duration: until 48 hours post-extubation
Outcomes Mortality
Adverse events
Follow-up duration: not stated
Notes Country: USA
Setting: 24 hospitals, adult ICU
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Eggimann 1999
Methods Random sequence generation: Yes (block)
Allocation concealment: Yes (pharmacy allocation)
Blinding (subjects/investigators): Yes
Blinding (outcome assessors): Yes
Intention-to-treat analysis: No
Number excluded /number randomized: 6/49 (12%)
Participants Inclusion: recent abdominal surgery, recurrent gastrointestinal tract perforation, or anastomotic leakage
Number randomized: 49
Percentage post-surgical: 100%
Percentage colonized with Candida at baseline: 40%
Interventions 1. Fluconazole 400 mg/day IV
2. Placebo
Intervention duration: until “complete resolution of intra-abdominal disease” (median 15-17 days)
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Eggimann 1999 (Continued)
Outcomes Mortality
Proven IFI
Proven IFI with azole-resistant species.
Fungal colonization
Fungal colonization with azole-resistant species
Adverse events
Follow-up duration: until one week post-prophylaxis
Notes Country: Switzerland
Setting: two hospitals, adult surgical/medical ICU
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Garbino 2002
Methods Random sequence generation: Unclear
Allocation concealment: Yes (“blinded list”)
Blinding (subjects/investigators): Yes
Blinding (outcome assessors): Unclear
Intention-to-treat analysis: Unclear
Number excluded /number randomized: 16/220 (7%)
Participants Inclusion: mechaniscal ventilation >48 hours and expected further 72 hours
Number randomized: 220
Percentage post-surgical: 60%
Percentage colonized with Candida at baseline: 48%
Interventions 1. Fluconazole 100 mg/day IV
2. Placebo
Intervention duration: until withdrawal from mechanical ventilation
Outcomes Mortality
Proven IFI
Suspected IFI
Proven IFI with azole-resistant species
Superficial FI
Fungal colonization
Fungal colonization with azole-resistant species
Adverse events
Follow-up duration: at least 30 days
Notes Country: Switzerland
Setting: single hospital, adult surgical/medical ICU
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Garbino 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
He 2003
Methods Random sequence generation: Unclear
Allocation concealment: Unclear
Blinding (subjects/investigators): Unclear
Blinding (outcome assessors): Unclear
Intention-to-treat analysis: Yes
Number excluded /number randomized: 0/70 (0%)
Participants Inclusion: severe pancreatitis with at least one of “elderly”, organ dysfunction, total parenteral nutrition,
corticosteroids, gastrointestinal fistula, broad-spectrum antibiotics)
Number randomized: 70
Percentage post-surgical: not stated
Percentage colonized with Candida at baseline: not stated
Interventions 1. Fluconazole 100 mg/day IV
2. “Garlicin” 120 mg/day IV
3. Control (neither fluconazole or “garlicin”)
Intervention duration: “until relief of predisposing condition”
Outcomes Proven IFI
Follow-up duration: not stated
Notes Country: China
Setting: ?single hospital, ?ward and/or ICU
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Jacobs 2003
Methods Random sequence generation: Uclear
Allocation concealment: Yes (pharmacy allocation)
Blinding (subjects/investigators): Yes
Blinding (outcome assessors): Unclear
Intention-to-treat analysis: Yes
Number excluded /number randomized: 0/71 (0%)
Participants Inclusion: septic shock from gastrointestinal tract perforation or nosocomial pneumonia
Number randomized: 71
Percentage post-surgical: 65%
Percentage colonized with Candida at baseline: 6%
Interventions 1. Fluconazole 200 mg/day IV
2. Placebo
Intervention duration: for duration of septic shock
Outcomes Mortality
Proven IFI
Proven IFI with azole-resistant species
Fungal colonization
Follow-up duration: 30 days
Notes Country: Saudi Arabia
Setting: single hospital, adult surgical/medical ICU
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Parizkova 2000
Methods Random sequence generation: Unclear
Allocation concealment: Unclear (envelopes ?sealed)
Blinding (subjects/investigators): Unclear
Blinding (outcome assessors): Unclear
Intention-to-treat analysis: Yes
Number excluded /number randomized: 0/38 (0%)
Participants Inclusion: admitted to ICU <5 days, receipt of antibiotics >24 hours, mechaniscal ventilation >48 hours
Number randomized: 38
Percentage post-surgical: >37%
Percentage colonized with Candida at baseline: not stated
Interventions 1. Fluconazole 100 mg/day IV
2. Control (no fluconazole)
Intervention duration: for duration of ICU admission
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Parizkova 2000 (Continued)
Outcomes Mortality
Proven IFI
Proven IFI with azole-resistant species
Fungal colonization
Fungal colonization with azole-resistant species
Follow-up duration: not stated
Notes Country: Czech Republic
Setting: single hospital, adult ICU
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Pelz 2001
Methods Random sequence generation: Yes (block)
Allocation concealment: Yes (pharmacy allocation)
Blinding (subjects/investigators): Yes
Blinding (outcome assessors): Yes
Intention-to-treat analysis: Yes
Number excluded /number randomized: 0/260 (0%)
Participants Inclusion: expected length of ICU stay >3 days
Number randomized: 260
Percentage post-surgical: 91%
Percentage colonized with Candida at baseline: 75%
Interventions 1. Fluconazole 800 mg orally then 400 mg/day orally
2.Placebo
Intervention duration: until ICU discharge (mean 5 days)
Outcomes Mortality
Proven IFI
Suspected IFI
Proven IFI with azole-resistant species
Superficial FI
Follow-up duration: until 3 days post-ICU discharge
Notes Country: USA
Setting: single hospital, adult surgical ICU
Risk of bias
Bias Authors’ judgement Support for judgement
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Pelz 2001 (Continued)
Allocation concealment? Low risk A - Adequate
Sandven 2002
Methods Random sequence generation: Yes (computer)
Allocation concealment: Yes (computer allocation)
Blinding (subjects/investigators): Yes
Blinding (outcome assessors): Unclear
Intention-to-treat analysis: Yes
Number excluded /number randomized: 8/117 (7%)
Participants Inclusion: gastrointestinal perforation
Number randomized: 117
Percentage post-surgical: 100%
Percentage colonized with Candida at baseline: not stated
Interventions 1. Fluconazole 400 mg IV single dose
2. Placebo
Intervention duration: single dose
Outcomes Mortality
Proven IFI
Suspected IFI
Follow-up duration: not stated
Notes Country: Norway
Setting: 13 hospitals, adult surgical patients
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Savino 1994
Methods Random sequence generation: Unclear
Allocation concealment: Yes (sealed envelopes)
Blinding (subjects/investigators): No
Blinding (outcome assessors): Unclear
Intention-to-treat analysis: No
Number excluded /number randomized: 0/292 (0%)
Participants Inclusion: expected length of stay >48 hours
Number randomized: 292
Percentage post-surgical: 79%
Percentage colonized with Candida at baseline: not stated
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Savino 1994 (Continued)
Interventions 1. Ketoconazole 200 mg/day orally
2. Clotrimazole 30 mg/day orally
3. Nystatin 8 million units/day orally
4. Control (no antifungal)
Intervention duration: until ICU discharge (mean 8-16 days)
Outcomes Mortality
Proven IFI
Fungal colonization
Follow-up duration: not stated
Notes Country: USA
Setting: single hospital, adult surgical ICU
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Slotman 1987
Methods Random sequence generation: Unclear
Allocation concealment: Unclear
Blinding (subjects/investigators): Yes
Blinding (outcome assessors): Unclear
Intention-to-treat analysis: No
Number excluded /number randomized: 17/74 (23%)
Participants Inclusion: >2 risk factors, no fungal colonization
Number randomized: 74
Percentage post-surgical: 97%
Percentage colonized with Candida at baseline: 20%
Interventions 1. Ketoconazole 200 mg/day orally
2. Placebo
Intervention duration: until ICU discharge (maximum 21 days)
Outcomes Mortality
Proven IFI
Proven IFI with azole-resistant species
Fungal colonization
Fungal colonization with azole-resistant species
Follow-up duration: not stated
Notes Country: USA
Setting: single hospital, adult surgical ICU
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Slotman 1987 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Yu 1993
Methods Random sequence generation: Unclear
Allocation concealment: Unclear
Blinding (subjects/investigators): Yes
Blinding (outcome assessors): Unclear
Intention-to-treat analysis: Yes
Number excluded /number randomized: 0/56 (0%)
Participants Inclusion: sepsis
Number randomized: 56
Percentage post-surgical: ?100%
Percentage colonized with Candida at baseline: not stated
Interventions 1. Ketoconazole 400 mg/day orally
2. Placebo
Intervention duration: until ICU discharge (maximum 21 days)
Outcomes Mortality
Fungal colonization
Adverse events
Follow-up duration: not stated
Notes Country: USA
Setting: single hospital, adult surgical ICU
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
FI = fungal infections
IFI = invasive fungal infections
IV = intraveneous
ICU = intensive care unit
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allen 2000 Intervention (glutamine-containing total parenteral nutrition fluid) not relevant
Bellman 1995 Commentary
DeVries 1998 Review
Earl-Salotti 1995 Review
Evans 1975 Not randomized
Frazee 1995 Review
Kicklighter 2001 Participants not relevant (neonates)
Moral 1994 Not randomized
Ohnmacht 2001 Participants not relevant (patients receiving interleukin-2)
Rosemurgy 1995 Outcomes not relevant
Schilling 2001 Not randomized
Van Saene 2002 Review
Vandewoude 1997 Not randomized
Wainer 1992 Participants not relevant (neonates)
Weydert 1971 Intervention not relevant (selective decontamination of the digestive tract)
Yahwak 2002 Review
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D A T A A N D A N A L Y S E S
Comparison 1. Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 11 1500 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.59, 0.97]
1.1 Fluconazole 7 849 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.56, 1.07]
1.2 Ketoconazole 4 651 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.42, 1.12]
2 Proven invasive fungal infection 10 1260 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.31, 0.68]
2.1 Fluconazole 8 897 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.32, 0.71]
2.2 Ketoconazole 2 363 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.07, 1.31]
3 Proven invasive fungal infection
(azole-resistant Candida
species)
7 805 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.22, 1.72]
3.1 Fluconazole 6 734 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.22, 1.96]
3.2 Ketoconazole 1 71 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.14]
4 Proven invasive fungal infection
(moulds)
7 805 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Fluconazole 6 734 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Ketoconazole 1 71 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Suspected invasive fungal
infection
4 696 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.25, 5.13]
5.1 Fluconazole 4 696 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.25, 5.13]
5.2 Ketoconazole 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Proven or suspected invasive
fungal infection
4 696 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.40, 1.02]
6.1 Fluconazole 4 696 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.40, 1.02]
6.2 Ketoconazole 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Superficial fungal infection 3 587 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.27, 1.29]
7.1 Fluconazole 3 587 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.27, 1.29]
7.2 Ketoconazole 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Fungal colonization 8 792 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.50, 0.73]
8.1 Fluconazole 5 375 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.42, 0.74]
8.2 Ketoconazole 3 417 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.47, 0.94]
9 Fungal colonization
(azole-resistant Candida
species)
5 309 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.44, 2.95]
9.1 Fluconazole 4 252 Risk Ratio (M-H, Random, 95% CI) 1.74 [0.64, 4.71]
9.2 Ketoconazole 1 57 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.02, 1.44]
10 Adverse effects requiring
cessation
5 655 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.37, 1.94]
10.1 Fluconazole 3 367 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.22, 2.57]
10.2 Ketoconazole 2 288 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.20, 7.59]
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Analysis 1.1. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 1 Mortality.
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 1 Mortality
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 12/60 12/60 8.7 % 1.00 [ 0.49, 2.05 ]
Eggimann 1999 7/23 10/20 8.0 % 0.61 [ 0.29, 1.30 ]
Garbino 2002 41/105 43/103 20.3 % 0.94 [ 0.67, 1.30 ]
Jacobs 2003 7/32 21/39 8.7 % 0.41 [ 0.20, 0.83 ]
Parizkova 2000 4/18 0/20 0.7 % 9.95 [ 0.57, 172.84 ]
Pelz 2001 14/130 16/130 9.5 % 0.88 [ 0.45, 1.72 ]
Sandven 2002 4/53 8/56 4.1 % 0.53 [ 0.17, 1.65 ]
Subtotal (95% CI) 421 428 59.9 % 0.77 [ 0.56, 1.07 ]
Total events: 89 (Antifungal), 110 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 8.73, df = 6 (P = 0.19); I2 =31%
Test for overall effect: Z = 1.54 (P = 0.12)
2 Ketoconazole
ARDS Network 2000 41/117 40/117 19.3 % 1.03 [ 0.72, 1.46 ]
Savino 1994 4/65 37/227 5.2 % 0.38 [ 0.14, 1.02 ]
Slotman 1987 11/35 15/36 10.5 % 0.75 [ 0.40, 1.41 ]
Yu 1993 4/26 11/28 5.0 % 0.39 [ 0.14, 1.08 ]
Subtotal (95% CI) 243 408 40.1 % 0.68 [ 0.42, 1.12 ]
Total events: 60 (Antifungal), 103 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 6.28, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 664 836 100.0 % 0.76 [ 0.59, 0.97 ]
Total events: 149 (Antifungal), 213 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 14.81, df = 10 (P = 0.14); I2 =32%
Test for overall effect: Z = 2.18 (P = 0.029)
0.1 0.2 0.5 1 2 5 10
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Analysis 1.2. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 2 Proven invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 2 Proven invasive fungal infection
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 8/61 12/60 21.9 % 0.66 [ 0.29, 1.49 ]
Eggimann 1999 4/25 9/22 13.9 % 0.39 [ 0.14, 1.09 ]
Garbino 2002 5/104 11/102 14.1 % 0.45 [ 0.16, 1.24 ]
He 2003 2/22 7/23 6.9 % 0.30 [ 0.07, 1.28 ]
Jacobs 2003 0/32 1/39 1.5 % 0.40 [ 0.02, 9.59 ]
Parizkova 2000 0/18 0/20 Not estimable
Pelz 2001 7/130 16/130 20.2 % 0.44 [ 0.19, 1.03 ]
Sandven 2002 5/53 10/56 14.6 % 0.53 [ 0.19, 1.44 ]
Subtotal (95% CI) 445 452 93.2 % 0.47 [ 0.32, 0.71 ]
Total events: 31 (Antifungal), 66 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.67 (P = 0.00024)
2 Ketoconazole
Savino 1994 1/65 8/227 3.5 % 0.44 [ 0.06, 3.43 ]
Slotman 1987 1/35 5/36 3.4 % 0.21 [ 0.03, 1.67 ]
Subtotal (95% CI) 100 263 6.8 % 0.30 [ 0.07, 1.31 ]
Total events: 2 (Antifungal), 13 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 545 715 100.0 % 0.46 [ 0.31, 0.68 ]
Total events: 33 (Antifungal), 79 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.82, df = 8 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 3.96 (P = 0.000074)
0.1 0.2 0.5 1 2 5 10
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Analysis 1.3. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 3 Proven invasive fungal infection (azole-resistant Candida species).
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 3 Proven invasive fungal infection (azole-resistant Candida species)
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 0/60 2/58 11.6 % 0.19 [ 0.01, 3.94 ]
Eggimann 1999 1/23 1/20 14.4 % 0.87 [ 0.06, 13.02 ]
Garbino 2002 1/103 0/101 10.4 % 2.94 [ 0.12, 71.39 ]
Jacobs 2003 0/32 0/39 Not estimable
Parizkova 2000 0/18 0/20 Not estimable
Pelz 2001 3/130 5/130 53.1 % 0.60 [ 0.15, 2.46 ]
Subtotal (95% CI) 366 368 89.5 % 0.66 [ 0.22, 1.96 ]
Total events: 5 (Antifungal), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.54, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.46)
2 Ketoconazole
Slotman 1987 0/35 1/36 10.5 % 0.34 [ 0.01, 8.14 ]
Subtotal (95% CI) 35 36 10.5 % 0.34 [ 0.01, 8.14 ]
Total events: 0 (Antifungal), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 401 404 100.0 % 0.62 [ 0.22, 1.72 ]
Total events: 5 (Antifungal), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.69, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
0.1 0.2 0.5 1 2 5 10
Favours antifungal Favours control
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Analysis 1.4. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 4 Proven invasive fungal infection (moulds).
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 4 Proven invasive fungal infection (moulds)
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 0/60 0/58 Not estimable
Eggimann 1999 0/23 0/20 Not estimable
Garbino 2002 0/103 0/101 Not estimable
Jacobs 2003 0/32 0/39 Not estimable
Parizkova 2000 0/18 0/20 Not estimable
Pelz 2001 0/130 0/130 Not estimable
Subtotal (95% CI) 366 368 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Ketoconazole
Slotman 1987 0/35 0/36 Not estimable
Subtotal (95% CI) 35 36 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 401 404 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours antifungal Favours control
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Analysis 1.5. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 5 Suspected invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 5 Suspected invasive fungal infection
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 5/61 1/60 23.9 % 4.92 [ 0.59, 40.86 ]
Garbino 2002 1/104 3/102 22.5 % 0.33 [ 0.03, 3.09 ]
Pelz 2001 2/130 6/130 30.2 % 0.33 [ 0.07, 1.62 ]
Sandven 2002 4/53 1/56 23.4 % 4.23 [ 0.49, 36.61 ]
Subtotal (95% CI) 348 348 100.0 % 1.14 [ 0.25, 5.13 ]
Total events: 12 (Treatment), 11 (Control)
Heterogeneity: Tau2 = 1.29; Chi2 = 6.72, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.18 (P = 0.86)
2 Ketoconazole
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 348 348 100.0 % 1.14 [ 0.25, 5.13 ]
Total events: 12 (Treatment), 11 (Control)
Heterogeneity: Tau2 = 1.29; Chi2 = 6.72, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.18 (P = 0.86)
0.1 0.2 0.5 1 2 5 10
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Analysis 1.6. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 6 Proven or suspected invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 6 Proven or suspected invasive fungal infection
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 13/61 13/60 29.6 % 0.98 [ 0.50, 1.94 ]
Garbino 2002 6/104 14/102 19.6 % 0.42 [ 0.17, 1.05 ]
Pelz 2001 9/130 22/130 26.8 % 0.41 [ 0.20, 0.85 ]
Sandven 2002 9/53 11/56 24.0 % 0.86 [ 0.39, 1.92 ]
Subtotal (95% CI) 348 348 100.0 % 0.64 [ 0.40, 1.02 ]
Total events: 37 (Antifungal), 60 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.35, df = 3 (P = 0.23); I2 =31%
Test for overall effect: Z = 1.89 (P = 0.059)
2 Ketoconazole
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 348 348 100.0 % 0.64 [ 0.40, 1.02 ]
Total events: 37 (Antifungal), 60 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.35, df = 3 (P = 0.23); I2 =31%
Test for overall effect: Z = 1.89 (P = 0.059)
0.1 0.2 0.5 1 2 5 10
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Analysis 1.7. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 7 Superficial fungal infection.
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 7 Superficial fungal infection
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 4/61 7/60 43.5 % 0.56 [ 0.17, 1.82 ]
Garbino 2002 2/104 6/102 24.2 % 0.33 [ 0.07, 1.58 ]
Pelz 2001 4/130 4/130 32.3 % 1.00 [ 0.26, 3.91 ]
Subtotal (95% CI) 295 292 100.0 % 0.59 [ 0.27, 1.29 ]
Total events: 10 (Antifungal), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
2 Ketoconazole
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 295 292 100.0 % 0.59 [ 0.27, 1.29 ]
Total events: 10 (Antifungal), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
0.1 0.2 0.5 1 2 5 10
Favours antifungal Favours control
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Analysis 1.8. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 8 Fungal colonization.
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 8 Fungal colonization
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 14/60 32/57 14.4 % 0.42 [ 0.25, 0.69 ]
Eggimann 1999 7/23 14/20 8.2 % 0.43 [ 0.22, 0.86 ]
Garbino 2002 29/55 40/51 45.5 % 0.67 [ 0.50, 0.90 ]
Jacobs 2003 2/32 4/39 1.4 % 0.61 [ 0.12, 3.12 ]
Parizkova 2000 18/18 20/20 Not estimable
Subtotal (95% CI) 188 187 69.6 % 0.55 [ 0.42, 0.74 ]
Total events: 70 (Antifungal), 110 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.61, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 4.02 (P = 0.000059)
2 Ketoconazole
Savino 1994 9/65 50/227 8.9 % 0.63 [ 0.33, 1.21 ]
Slotman 1987 16/35 23/36 19.9 % 0.72 [ 0.46, 1.11 ]
Yu 1993 2/26 6/28 1.7 % 0.36 [ 0.08, 1.62 ]
Subtotal (95% CI) 126 291 30.4 % 0.66 [ 0.47, 0.94 ]
Total events: 27 (Antifungal), 79 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
Total (95% CI) 314 478 100.0 % 0.60 [ 0.50, 0.73 ]
Total events: 97 (Antifungal), 189 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.73, df = 6 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 5.11 (P < 0.00001)
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Analysis 1.9. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 9 Fungal colonization (azole-resistant Candida species).
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 9 Fungal colonization (azole-resistant Candida species)
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 2/60 2/57 21.5 % 0.95 [ 0.14, 6.52 ]
Eggimann 1999 2/23 1/20 15.4 % 1.74 [ 0.17, 17.78 ]
Garbino 2002 3/24 2/30 26.5 % 1.88 [ 0.34, 10.33 ]
Parizkova 2000 3/18 1/20 17.4 % 3.33 [ 0.38, 29.25 ]
Subtotal (95% CI) 125 127 80.8 % 1.74 [ 0.64, 4.71 ]
Total events: 10 (Antifungal), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
2 Ketoconazole
Slotman 1987 1/27 6/30 19.2 % 0.19 [ 0.02, 1.44 ]
Subtotal (95% CI) 27 30 19.2 % 0.19 [ 0.02, 1.44 ]
Total events: 1 (Antifungal), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Total (95% CI) 152 157 100.0 % 1.13 [ 0.44, 2.95 ]
Total events: 11 (Antifungal), 12 (Control)
Heterogeneity: Tau2 = 0.14; Chi2 = 4.54, df = 4 (P = 0.34); I2 =12%
Test for overall effect: Z = 0.26 (P = 0.80)
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Analysis 1.10. Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal,
Outcome 10 Adverse effects requiring cessation.
Review: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Comparison: 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome: 10 Adverse effects requiring cessation
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fluconazole
Ables 2000 0/61 2/59 7.3 % 0.19 [ 0.01, 3.95 ]
Eggimann 1999 0/23 0/20 Not estimable
Garbino 2002 4/103 4/101 32.6 % 0.98 [ 0.25, 3.81 ]
Subtotal (95% CI) 187 180 39.9 % 0.75 [ 0.22, 2.57 ]
Total events: 4 (Antifungal), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
2 Ketoconazole
ARDS Network 2000 4/117 1/117 13.7 % 4.00 [ 0.45, 35.25 ]
Yu 1993 4/26 7/28 46.5 % 0.62 [ 0.20, 1.86 ]
Subtotal (95% CI) 143 145 60.1 % 1.24 [ 0.20, 7.59 ]
Total events: 8 (Antifungal), 8 (Control)
Heterogeneity: Tau2 = 1.05; Chi2 = 2.35, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 330 325 100.0 % 0.85 [ 0.37, 1.94 ]
Total events: 12 (Antifungal), 14 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 3.25, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 0.39 (P = 0.70)
0.1 0.2 0.5 1 2 5 10
Favours antifungal Favours control
A D D I T I O N A L T A B L E S
Table 1. Definitions of fungal infections used in included studies
Trial Proven IFI Suspected IFI Superficial FI
Ables 2000 “Documented candidiasis”: positive
culture from respiratory, mucosal,
or peritoneal specimens
Compatible clinical illness (includ-
ing SIRS) but no evidence of bacte-
rial or other cause
Fungal UTI, thrush, skin lesions
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Table 1. Definitions of fungal infections used in included studies (Continued)
Eggimann 1999 Clinical plus positive culture/histol-
ogy of sterile site specimen or ab-
dominal drain effluent
NA NA
Garbino 2002 Clinical plus positive culture of ster-
ile site specimen or BAL (>10,000
cfu/mL) with radiological infiltrates
Commencement of systemic anti-
fungal therapy with clinical but no
microbiological evidence of IFI
Fungal superficial wound, UTI, or
mucocutaneous infection
He 2003 Clinical plus positive culture from
sterile site specimen or bile, sputum,
pus, throat, urine, or stool
NA NA
Jacobs 2003 Positive culture/histology of sterile
site specimen
NA Culture of mucosal surface speci-
mens
Parizkova 2000 Clinical plus positive culture/histol-
ogy of sterile site specimen
NA Clinical plus culture of superficial
site specimens
Pelz 2001 Clinical plus positive culture/histol-
ogy of sterile site specimen, intrader-
mal catheter tip (>15 cfu), or deep
surgical site specimen (on debride-
ment)
Commencement of antifungal ther-
apy with clinical evidence of IFI and
fungal colonisation
Fungal UTI
Sandven 2002 Clinical plus positive culture of
blood, intrabdominal drain fluid, or
other (unspecified) sites
Commencement of systemic anti-
fungal therapy with clinical but no
microbiological evidence of IFI
NA
Savino 1994 Positive culture of sterile site speci-
men or > 2 other (unspecified) sites
NA NA
Slotman 1987 Positive culture of sterile site or in-
vasive burn wound
NA NA
Weidemann 2000 NA NA NA
Yu 1993 NA NA NA
Table 2. Subgroup and sensitivity analyses
Variable Category No. studies RR (95%CI) IFI
SUBGROUP ANALYSES:
Definition of invasive fungal in-
fection conforms to that used in
this review
Yes 5 0.41 (0.24 to 0.69)
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Table 2. Subgroup and sensitivity analyses (Continued)
No 4 0.53 (0.30 to 0.93)
Fluconazole dose >/=400 mg/day 4 0.50 (0.30 to 0.80)
<400 mg/day 3 0.39 (0.17 to 0.88)
Post-surgical patients (%) >/=75% 5 0.43 (0.26 to 0.71)
<75% 3 0.56 (0.03 to 1.04)
SENSITIVITY ANALYSES:
Analysis model Random effects 0.46 (0.31 to 0.68)
Fixed effects 0.45 (0.31 to 0.66)
Randomized sequence genera-
tion
Adequate 4 0.50 (0.32 to 0.80)
Uncertain 5 0.37 (0.18 to 0.75)
Allocation concealment Adequate 6 0.45 (0.28 to 0.71)
Uncertain 3 0.49 (0.25 to 0.97)
Blinding of outcome assessors Yes 2 0.42 (0.22 to 0.81)
No 7 0.48 (0.30 to 0.78)
Intention-to-treat analysis Yes 4 0.44 (0.24 to 0.78)
No 5 0.48 (0.29 to 0.80)
Table 3. Applicability of meta-analysis results
Estimated risk Examples Incid. w/o prophy-
lax
Incid. w/ prophylax No. avoided NNT (95%CI)
Low (1%) Absence of risk fac-
tors (based on Rex
2001)
1 0.47 0.53 188 (147-345)
Average (2%) Unselected ICU
population (based on
Rex 2001)
2 0.94 1.06 94 (74-172)
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Table 3. Applicability of meta-analysis results (Continued)
High (11%) One of new onset
haemodial-
ysis, diabetes, total
parenteral nutrition
prior to ICU entry,
or broad-spectrum
antibiotics (based on
Paphitou 2005)
11 5.2 5.8 17 (13-31)
High (17%) One of new onset
haemodial-
ysis, diabetes, or to-
tal parenteral nutri-
tion prior to ICU en-
try (based on Paphi-
tou 2005)
17 8.0 9.0 11 (9-20)
Highest (20%) One of new onset
haemodial-
ysis, diabetes, or to-
tal parenteral nutri-
tion prior to ICU
entry AND broad-
spectrum antibiotics
(based on Paphitou
2005)
20 9.4 10.6 9 (7-17)
A P P E N D I C E S
Appendix 1. Search strategies for electronic databases
Database Search strategy
Cochrane Central Register of Controlled Trials #1 MeSH descriptor Antifungal Agents explode all trees in MeSH products
#2 antifungal in All Fields, from 1800 to 2004 in all products
#3 fluconazole in All Fields, from 1800 to 2004 in all products
#4 itraconazole in All Fields, from 1800 to 2004 in all products
#5 ketoconazole in All Fields in all products
#6 voriconazole in All Fields in all products
#7 amphotericin in All Fields in all products
#8 ambisome in All Fields in all products
41Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#9 amphotec in All Fields in all products
#10 amphocil in All Fields in all products
#11 abelcet in All Fields in all products
#12 caspofungin in All Fields in all products
#13 flucytosine in All Fields in all products
#14 miconazole in All Fields in all products
#15 econazole in All Fields in all products
#16 clotrimazole in All Fields in all products
#17 nystatin in All Fields in all products
#18 MeSH descriptor Mycoses explode all trees in MeSH products
#19 fung* in All Fields in all products
#20 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR
#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19)
#21 MeSH descriptor Critical Care explode all trees in MeSH products
#22 intensive in All Fields in all products
#23 critic* in All Fields in all products
#24 surg* in All Fields in all products
#25 (#21 OR #22 OR #23 OR #24)
#26 (#20 AND #25)
MEDLINE (OVID) 1 exp antifungal agents/
2 exp mycoses/
3 fung$.tw.
4 fluconazole.tw.
5 diflucan.tw.
6 itraconazole.tw.
7 sporanox.tw.
8 ketoconazole.tw.
9 nizoral.tw.
10 voriconazole.tw.
11 amphotericin.tw.
12 ambisome.tw.
13 amphotec.tw.
14 abelcet.tw.
15 flucytosine.tw.
16 nystatin.tw.
17 miconazole.tw.
18 (echinocandin$ or caspofungin).tw.
19 (select$ adj5 decontam$).tw.
20 or/1-19
21 exp Intensive Care Units/
22 intensive care.tw.
23 critical$.tw.
24 surg$.tw.
25 or/21-24
26 20 and 25
27 randomized controlled trial.pt.
28 controlled clinical trial.pt.
29 randomized controlled trials/
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(Continued)
30 Random allocation/
31 Double-blind method/
32 Single-blind method/
33 exp Evaluation studies/
34 exp clinical-trials/
35 clinical trial.pt.
36 (clin$ adj5 trial$).tw.
37 ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
38 exp Placebos/
39 placebo$.tw.
40 random$.tw.
41 exp Research design/
42 or/27-41
43 26 and 42
EMBASE (OVID) 1 exp antifungal agent/
2 fluconazole.tw.
3 diflucan.tw.
4 itraconazole.tw.
5 sporanox.tw.
6 ketoconazole.tw.
7 nizoral.tw.
8 voriconazole.tw.
9 vfend.tw.
10 amphotericin.tw.
11 ambisome.tw.
12 amphotec.tw.
13 amphocil.tw.
14 abelcet.tw.
15 fungizone.tw.
16 flucytosine.tw.
17 nystatin.tw.
18 miconazole.tw.
19 echinocandin$.tw.
20 caspofungin.tw.
21 (select$ adj decontam$).tw.
22 exp mycosis/
23 fung$.tw.
24 or/1-23
25 exp intensive care unit/
26 intensive.tw.
27 critic$.tw.
28 surg$.tw.
29 or/25-28
30 24 and 29
31 exp controlled study/ or controlled study.ti,ab,hw,tn,mf.
32 exp statistical analysis/ or clinical study.ti,ab,hw,tn,mf.
33 exp major clinical study/ or major clinical study.ti,ab,hw,tn,mf.
34 exp randomized controlled trial/ or randomised controlled study.ti,ab,hw,tn,
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(Continued)
mf.
35 exp randomized controlled trial/ or randomized controlled study.ti,ab,hw,tn,
mf.
36 random$.ti,ab,hw,tn,mf.
37 exp double blind procedure/ or double blind procedure.ti,ab,hw,tn,mf.
38 exp single blind procedure/ or single blind procedure.ti,ab,hw,tn,mf.
39 exp multicenter study/ or multicenter study.ti,ab,hw,tn,mf.
40 exp placebo/ or placebo.ti,ab,hw,tn,mf.
41 or/31-40
42 (human not animal).sh,de,hw.
43 41 and 42
44 30 and 43
WH A T ’ S N E W
Last assessed as up-to-date: 8 November 2005.
Date Event Description
31 May 2012 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 3, 2004
Review first published: Issue 1, 2006
Date Event Description
25 July 2008 Amended Converted to new review format.
8 November 2005 New citation required and conclusions have changed Substantive amendment
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N O T E S
Please note: The author originally published:“Antifungal agents for preventing fungal infections in non-neutropenic critically- ill
patients and solid organ transplant recipients” with the Cochrane Gynaecological Cancer Group. The author then split the title and
published a further protocol: “Antifungal agents for preventing fungal infections in solid organ transplant recipients” with the Cochrane
Renal Group. The Cochrane Gynaecological Cancer Group has kindly agreed to the author splitting the original published protocol
again and registering it with the Anaesthesia Group as: “Antifungal agents for preventing fungal infections in non-neutropenic critically
ill patients”.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Critical Illness [mortality]; Amphotericin B [therapeutic use]; Antifungal Agents [∗therapeutic use]; Fluconazole [therapeutic use];
Immunocompromised Host; Mycoses [mortality; ∗prevention & control]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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